JP2010529860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529860A5 JP2010529860A5 JP2010512391A JP2010512391A JP2010529860A5 JP 2010529860 A5 JP2010529860 A5 JP 2010529860A5 JP 2010512391 A JP2010512391 A JP 2010512391A JP 2010512391 A JP2010512391 A JP 2010512391A JP 2010529860 A5 JP2010529860 A5 JP 2010529860A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- fusion protein
- amino acids
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 16
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020001756 ligand binding domains Proteins 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000036252 glycation Effects 0.000 claims 2
- 102000049409 human MOK Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94399407P | 2007-06-14 | 2007-06-14 | |
| US60/943,994 | 2007-06-14 | ||
| PCT/US2008/066956 WO2008157378A2 (en) | 2007-06-14 | 2008-06-13 | Page fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015038891A Division JP5887441B2 (ja) | 2007-06-14 | 2015-02-27 | Ｒａｇｅ融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529860A JP2010529860A (ja) | 2010-09-02 |
| JP2010529860A5 true JP2010529860A5 (enExample) | 2011-07-28 |
| JP5706688B2 JP5706688B2 (ja) | 2015-04-22 |
Family
ID=40156919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512391A Active JP5706688B2 (ja) | 2007-06-14 | 2008-06-13 | Ｒａｇｅ融合タンパク質 |
| JP2015038891A Active JP5887441B2 (ja) | 2007-06-14 | 2015-02-27 | Ｒａｇｅ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015038891A Active JP5887441B2 (ja) | 2007-06-14 | 2015-02-27 | Ｒａｇｅ融合タンパク質 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8398977B2 (enExample) |
| EP (1) | EP2158210B1 (enExample) |
| JP (2) | JP5706688B2 (enExample) |
| KR (2) | KR101595634B1 (enExample) |
| CN (1) | CN101842382A (enExample) |
| AU (1) | AU2008265983B2 (enExample) |
| BR (1) | BRPI0813452A2 (enExample) |
| CA (1) | CA2690056C (enExample) |
| CO (1) | CO6241158A2 (enExample) |
| EC (1) | ECSP099804A (enExample) |
| ES (1) | ES2564634T3 (enExample) |
| IL (1) | IL202443B (enExample) |
| MX (1) | MX2009013194A (enExample) |
| NZ (1) | NZ581550A (enExample) |
| PL (1) | PL2158210T3 (enExample) |
| RU (1) | RU2513695C2 (enExample) |
| WO (1) | WO2008157378A2 (enExample) |
| ZA (1) | ZA200908649B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781700B1 (en) | 2004-08-03 | 2014-03-19 | TransTech Pharma, LLC | Rage fusion proteins and methods of use |
| KR101580938B1 (ko) | 2007-06-01 | 2015-12-30 | 유니버시티 오브 매릴랜드, 발티모어 | 면역글로불린 불변영역 Ｆｃ 수용체 결합제 |
| DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
| EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
| MX368531B (es) | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| EP3511017A1 (en) | 2010-09-27 | 2019-07-17 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| AU2013211824B2 (en) * | 2012-01-27 | 2017-06-01 | Gliknik Inc. | Fusion proteins comprising IgG2 hinge domains |
| PL3016512T3 (pl) | 2013-07-05 | 2020-09-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rozpuszczalny CD33 do leczenia zespołów mielodysplastycznych (MDS) |
| AU2015318036B2 (en) | 2014-09-19 | 2021-07-01 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
| JP6679096B2 (ja) * | 2014-10-21 | 2020-04-15 | 学校法人 久留米大学 | Ｒａｇｅアプタマーおよびその用途 |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| ES2846024T7 (es) | 2015-07-24 | 2023-06-22 | Gliknik Inc | Proteínas de fusión de fragmentos de proteína humana para crear composiciones de Fc de inmunoglobulina multimerizada de forma ordenada con unión al complemento aumentada |
| EP4067386A1 (en) | 2016-02-19 | 2022-10-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
| US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| CA3026420A1 (en) | 2016-06-07 | 2017-12-14 | Gliknik Inc. | Cysteine-optimized stradomers |
| WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| JP2020503855A (ja) | 2016-12-09 | 2020-02-06 | グリックニック インコーポレイテッド | 多量体化ストラドマーｇｌ−２０４５の製造最適化 |
| IL266988B2 (en) | 2016-12-09 | 2024-11-01 | Gliknik Inc | Methods of treating inflammatory disorders with multivalent fc compounds |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| JP6964322B2 (ja) * | 2017-03-13 | 2021-11-10 | 学校法人 久留米大学 | ループス腎炎を処置または予防するための医薬組成物およびループス腎炎のバイオマーカー |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| US10913784B2 (en) | 2018-09-14 | 2021-02-09 | BioAge Labs, Inc. | RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| CN118043351A (zh) * | 2021-08-31 | 2024-05-14 | 上海医药集团股份有限公司 | 靶向Siglec15的抗原结合蛋白及其用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| EP0672141B1 (en) | 1992-10-23 | 2003-05-14 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| NO315930B1 (no) * | 1995-01-18 | 2003-11-17 | Picower Inst For Medical Res T | Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser |
| US5656261A (en) * | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
| EP1327887A3 (en) * | 1995-01-18 | 2008-12-10 | Synvista Therapeutics, Inc. | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products |
| AU1832797A (en) | 1996-01-26 | 1997-08-20 | Trustees Of Columbia University In The City Of New York, The | A polypeptide from lung extract which binds amyloid-beta peptide |
| US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| US5819341A (en) * | 1996-05-24 | 1998-10-13 | Simantob; Constance | Collapsible and convertible combination baby bed and baby carrier system |
| US6790442B1 (en) * | 1996-06-27 | 2004-09-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ |
| US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| WO1998040071A1 (en) | 1997-03-11 | 1998-09-17 | The General Hospital Corporation | Identification of agents for use in the treatment of alzheimer's disease |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| US6380165B1 (en) * | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US6706683B1 (en) * | 1998-09-29 | 2004-03-16 | Asahi Kasei Pharma Corporation | Method for controlling the release of granules |
| US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| HK1041293B (en) * | 1998-10-06 | 2008-01-25 | The Trustees Of Columbia University In The City Of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
| US6605642B2 (en) * | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
| US6787566B2 (en) * | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
| US6589944B1 (en) | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
| FR2797402B1 (fr) * | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| EP1307219A4 (en) | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| WO2001018060A1 (fr) | 1999-09-08 | 2001-03-15 | Toray Industries, Inc. | Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique |
| EP1287162A2 (en) | 1999-10-21 | 2003-03-05 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
| CA2382165A1 (en) * | 1999-12-08 | 2001-06-14 | Genset S.A. | Full-length human cdnas encoding potentially secreted proteins |
| AU4721901A (en) | 2000-02-25 | 2001-09-03 | Immunex Corp | Integrin antagonists |
| DE60129008T2 (de) * | 2000-04-14 | 2007-10-11 | Niadyne Corp., Tucson | Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten |
| AU2001255436A1 (en) | 2000-04-17 | 2001-10-30 | Transtech Pharma | Protein expression system arrays and use in biological screening |
| US7140063B2 (en) | 2000-05-05 | 2006-11-28 | Osborne James J | Multi-use and decorative bathing implement |
| US20020037538A1 (en) | 2000-05-09 | 2002-03-28 | Trepicchio William L. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
| US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US20020052475A1 (en) | 2000-07-20 | 2002-05-02 | Schering Ag | High affinity soluble interleukin-18 receptor |
| ATE342980T1 (de) | 2000-08-08 | 2006-11-15 | Zymogenetics Inc | Lösliche zcyctor 11 cytokinrezeptoren |
| US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| EA200300442A1 (ru) * | 2000-10-02 | 2003-10-30 | Редди Ю Эс Терапьютикс, Инк. | Способы и композиции для лечения воспалительных заболеваний |
| CA2424668A1 (en) | 2000-10-06 | 2002-04-11 | Novartis Ag | Targeting molecules for adenoviral vectors |
| AU2002213192A1 (en) | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
| PL366250A1 (en) | 2000-12-29 | 2005-01-24 | Reddy Us Therapeutics, Inc. | Detection of compounds that modulate inflammatory responses |
| DE10109466B4 (de) | 2001-02-28 | 2008-01-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren und Mittel zur Modifikation humaner Angiogenese |
| JP3837494B2 (ja) * | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| JP2006512900A (ja) * | 2002-08-16 | 2006-04-20 | ワイス | Ｒａｇｅ関連疾患の治療用組成物及び方法 |
| EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| EP1781700B1 (en) * | 2004-08-03 | 2014-03-19 | TransTech Pharma, LLC | Rage fusion proteins and methods of use |
| US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
| CA2581505A1 (en) * | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| CA2631240A1 (en) * | 2004-12-03 | 2006-06-08 | Xoma Technology Ltd. | Methods and materials for expression of a recombinant protein |
| US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
| EP1909834A2 (en) | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
| WO2007130302A2 (en) | 2006-05-05 | 2007-11-15 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| WO2008100470A2 (en) | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| WO2008137552A2 (en) | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
| WO2008153957A1 (en) | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
-
2008
- 2008-06-13 KR KR1020137011740A patent/KR101595634B1/ko active Active
- 2008-06-13 KR KR1020107000753A patent/KR101361355B1/ko active Active
- 2008-06-13 NZ NZ581550A patent/NZ581550A/en unknown
- 2008-06-13 MX MX2009013194A patent/MX2009013194A/es active IP Right Grant
- 2008-06-13 RU RU2010100913/10A patent/RU2513695C2/ru active
- 2008-06-13 ES ES08771049.7T patent/ES2564634T3/es active Active
- 2008-06-13 AU AU2008265983A patent/AU2008265983B2/en active Active
- 2008-06-13 CA CA2690056A patent/CA2690056C/en active Active
- 2008-06-13 CN CN200880102246A patent/CN101842382A/zh active Pending
- 2008-06-13 US US12/664,111 patent/US8398977B2/en active Active
- 2008-06-13 PL PL08771049T patent/PL2158210T3/pl unknown
- 2008-06-13 EP EP08771049.7A patent/EP2158210B1/en active Active
- 2008-06-13 JP JP2010512391A patent/JP5706688B2/ja active Active
- 2008-06-13 BR BRPI0813452A patent/BRPI0813452A2/pt not_active Application Discontinuation
- 2008-06-13 WO PCT/US2008/066956 patent/WO2008157378A2/en not_active Ceased
-
2009
- 2009-12-01 IL IL202443A patent/IL202443B/en active IP Right Grant
- 2009-12-07 ZA ZA200908649A patent/ZA200908649B/xx unknown
- 2009-12-11 CO CO09142110A patent/CO6241158A2/es active IP Right Grant
- 2009-12-14 EC EC2009009804A patent/ECSP099804A/es unknown
-
2013
- 2013-02-14 US US13/767,081 patent/US9066927B2/en active Active
-
2015
- 2015-02-27 JP JP2015038891A patent/JP5887441B2/ja active Active
- 2015-05-22 US US14/720,107 patent/US9399668B2/en active Active